Present preliminary SPEARHEAD-1 data at ASCO
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 4 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“June: preliminary data at American Society of Clinical Oncology (ASCO)”
What we found
Evidence strength A What the grades mean
A later 10-Q states that initial SPEARHEAD-1 Cohort 1 data were presented at ASCO on June 4, 2021, before the June 2021 deadline.
-
A Adaptimmune Therapeutics plc 10-Q filed 2021-08-09
“Initial data from Cohort 1 of this trial was presented at the American Society of Clinical Oncology (ASCO) on June 4, 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Preliminary SPEARHEAD-1 data at ASCO
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to congress acceptance
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Adaptimmune Therapeutics plc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ADAPY-024585 · Corrections policy